Actinogen Medical — XanaMIA passes interim analysis and marches on

Actinogen Medical’s interim analysis of its XanaMIA Phase IIb/III study of lead candidate Xanamem (emestedastat) in patients with mild-to-moderate Alzheimer’s disease (AD) was successful. The analysis surpassed interim futility thresholds and the independent data monitoring committee (DMC) recommended that the study proceed to completion without modification. The next major catalyst will be the top-line efficacy readout expected in November. The company also reported a A$17m capital increase, consisting of a A$12m now-completed offering to professional and sophisticated investors, and a A$5m share purchase plan (SPP) to existing investors. We expect the capital increase to boost Actinogen’s cash runway to mid-CY27, providing the company with ample flexibility to evaluate strategic or licensing options after the XanaMIA study readout. We now value Actinogen at A$778.3m or A$0.22 per share.